Tuesday, 30 May 2017

Gilead's HIV combination therapy succeeds in four late-stage studies

(Reuters) - Gilead Sciences Inc said on Tuesday its combination treatment for HIV met the main goal in four late-stage studies, paving the way for regulatory submissions.


No comments:

Post a Comment